Skip to main content

Sonig to head Lupin's generics, biosimilars business

Lupin has named Alok Sonig its new CEO of U.S. generics and global head, generics R&D and biosimilars. He will lead and have overall responsibility for Lupin's U.S. generics business, including research and development in India, the United States and the commercial side of the business in the states. He also will be responsible for the company's global biosimilars business.

Sonig was previously CEO of developed markets — United States, Canada, Europe and Japan — at Dr. Reddy's.

He joined Dr. Reddy’s in 2012 and ran their India business until 2015. Afterward, Sonig moved back to the states and began to lead to the North American business. Prior to Dr. Reddy’s, Sonig spent nearly 15 years at Bristol-Myers Squibb, where he held several positions of increasing responsibilities in general management, country leadership roles, global strategy and marketing.

“We are delighted to welcome Alok to Lupin. His global experience, strategic perspective, and operational focus will help accelerate our team’s efforts to strengthen and evolve our US generics business as we execute on near-term growth opportunities and navigate new platforms in complex generics and biosimilars.” Lupin's CEO, Vinita Gupta and managing director Nilesh Gupta, said.

Sonig will be based in Somerset, N.J. and will split his time between Lupin’s Somerset, Baltimore and India offices.
This ad will auto-close in 10 seconds